News
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares of Integra LifeSciences (NASDAQ: IART), a medical device company that focuses on surgical products, fell as much as 11% in early morning trading on Wednesday after the release of second-quarter
Why EXACT Sciences Corporation Is Rising Today
Shares of EXACT Sciences (NASDAQ: EXAS), a company focused on colon-cancer detection, rose as much as 13% in early morning trading on Wednesday in response to reporting better-than-expected
These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now
Despite overcoming a whopping $23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis, Wall Street thinks Pfizer (NYSE: PFE) still has
3 Stocks That Could Be Life-Changers
As the saying goes, "If there's no risk, there's no reward." No investment is without risk, but stocks that have life-changing potential tend to come with higher risks than your average investment. Of
3 Dividend Stocks That Thrive in Bear Markets
If you're looking to outsmart bears the next time they come knocking, you might want to consider adding PepsiCo (NYSE: PEP), Gilead Sciences (NASDAQ: GILD), and Colgate-Palmolive (NYSE: CL) to your
3 Key Things Every CAR-T Investor Should Watch
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis
Corning Looks to Sustain Its Momentum
Corning Incorporated (NYSE: GLW) is set to announce second-quarter 2017 results this Wednesday, July 26, 2017. With shares trading at a 10-year high after climbing more than 30% year to date as of
Why Reata Pharmaceuticals Is Rallying 17.5% Today
Reata Pharmaceuticals (NASDAQ: RETA) shares were surging 17.5% higher at 3 p.m. EST today, after the company reported that its experimental drug bardoxolone improved kidney function in patients with
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price is
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength
One look at the bottom line from Intuitive Surgical's (NASDAQ: ISRG) earnings release and you might think that the company had hit a speed bump. With the stock trading at 42 times trailing (non-GAAP)
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today
Stocks didn't move much on Thursday, and major benchmarks were narrowly mixed as earnings season kicked into full gear. Healthcare and utility stocks were generally higher, but the industrials and
Why Sarepta Therapeutics Stock Is Rising Today
Shares of the orphan drug specialist Sarepta Therapeutics (NASDAQ: SRPT) rose by as much as 15.5% in after-hours trading yesterday on heavy volume. This double-digit rally was sparked by a far
Why Sarepta Therapeutics Stock Rose After-Hours Wednesday
Shares of the orphan drug specialist Sarepta Therapeutics (NASDAQ: SRPT) rose by as much as 15.5% in after-hours trading yesterday on heavy volume. This double-digit rally was sparked by a far
Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still
Intuitive Surgical, Inc. in 3 Charts
It's still early, but Intuitive Surgical (NASDAQ: ISRG) stock could be on track to turn in its best performance of this decade. Shares of the robotic surgical systems company are up nearly 50% so far
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson & Johnson
Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today
Shares of rare-disease drugmaker Vertex Pharmaceuticals (NASDAQ: VRTX) are on the rise this morning thanks to the extremely positive data readouts for three trials assessing three different triple
Better Buy: Masimo Corporation vs. Zimmer Biomet Holdings Inc.
Over the past several years, Masimo Corporation (NASDAQ: MASI) and Zimmer Biomet Holdings Inc. (NYSE: ZBH) gained leading shares in their respective markets. Outmaneuvering competitors has driven